文献速递白血病造血干细胞移植与细胞治疗

未处理单倍体造血干细胞移植作为CAR-T后巩固治疗用于儿童及青年复发难治Ph阴性B-ALL

Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
PubMed 文献 · Leukemia · 2021-04-06

中位随访24.6个月,1年无事件生存率80.1%、总生存率92.3%、累积复发率14.1%;2年分别为76.0%、84.3%、19.7%。移植前MRD阳性是总生存不良的独立因素。

要点

  • CAR-T后桥接单倍体移植可获得较高的1年及2年无事件生存率和总生存率
  • 移植前MRD阳性与总生存不良独立相关(HR 4.201,P=0.045)
  • 未观察到移植物抗宿主病、治疗相关死亡或感染风险增加

核心结论

  • 未处理单倍体造血干细胞移植可能是CAR-T治疗后安全有效的巩固策略,可改善无事件生存和总生存。

研究设计与样本

  • CAR-T至移植的中位时间为61天,中位随访24.6个月。

主要发现

  • 1年无事件生存率80.1%(95%CI 69.0-90.9),总生存率92.3%(95%CI 85.0-99.5),累积复发率14.1%(95%CI 10.7-17.4)。
  • 2年无事件生存率76.0%(95%CI 64.2-87.7),总生存率84.3%(95%CI 74.3-94.3),累积复发率19.7%(95%CI 15.3-24.0)。
  • 未观察到2年移植物抗宿主病、治疗相关死亡或感染累积发生率增加。

关键数值与推荐

  • 移植前MRD阳性是总生存不良的独立因素(HR 4.201,95%CI 1.034-17.063,P=0.045)。

临床怎么用

  • 对CAR-T后达到缓解的复发难治Ph阴性B-ALL儿童及青年患者,可考虑桥接未处理单倍体造血干细胞移植以巩固疗效。
  • 移植前应评估MRD状态,MRD阳性提示预后不良需加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell transplantation (haplo-HSCT) is suitable for achieving sustainable remission. Therefore, we aimed to assess the efficacy and safety of bridging CAR-T therapy to haplo-HSCT. Fifty-two patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haplo-HSCT after CAR-T therapy were analyzed. The median time from CAR-T therapy to haplo-HSCT was 61 days. After a median follow-up of 24.6 months, the 1-year probabilities of event-free survival, overall survival, and cumulative incidence of relapse were 80.1% (95% confidence interval (CI), 69.0-90.9), 92.3% (95% CI, 85.0-99.5), and 14.1% (95% CI, 10.7-17.4), respectively, while the corresponding 2-year probabilities were 76.0% (95% CI, 64.2-87.7), 84.3% (95% CI, 74.3-94.3), and 19.7% (95% CI, 15.3-24.0), respectively. No increased risk of 2-year cumulative incidence of graft-versus-host disease, treatment-related mortality, or infection was observed. A pre-HSCT measurable residual disease-positive status was an independent factor associated with poor overall survival (hazard radio: 4.201, 95% CI: 1.034-17.063; P = 0.045). Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hu GH, Zhao XY, Zuo YX, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia. 2021. PMID: 33824464. doi:10.1038/s41375-021-01236-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。